Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Systematic review

Vol. 147 No. 0304 (2017)

The conservative and pharmacological management of chronic subdural haematoma: a systematic review

  • Jehuda Soleman
  • Fabio Nocera
  • Luigi Mariani
DOI
https://doi.org/10.57187/smw.2017.14398
Cite this as:
Swiss Med Wkly. 2017;147:w14398
Published
17.01.2017

Summary

Chronic subdural haematoma (cSDH), one of the most common neurosurgical entities, occurs typically in elderly patients. The incidence is expected to double by the year 2030, owing to the continuous aging of the population. Surgery is usually the treatment of choice, but conservative treatment may be a good alternative in some situations. We provide a systematic review of studies analysing the conservative treatment options and the natural history of cSDH. Of 231 articles screened, 35 were included in this systematic review. Studies evaluating the natural history and conservative treatment modalities of cSDH remain sparse and are predominantly of low level of evidence. The natural history of cSDH remains unclear and is analysed only in case reports or very small case series. “Wait and watch” or “wait and scan” management is indicated in patients with no or minor symptoms (Markwalder score 0–1). However, it seems that there are no clear clinical or radiological signs indicating whether the cSDH will resolve spontaneously or not (type C recommendation). In symptomatic patients who are not worsening or in a comatose state, oral steroid treatment might be an alternative to surgery (type C recommendation). Tranexamic acid proved effective in a small patient series (type C recommendation), but its risk of increasing thromboembolic events in patients treated with antithrombotic or anticoagulant medication is unclear. Angiotensin converting-enzyme inhibitors were evaluated only as adjuvant therapy to surgery, and their effect on the rate of recurrence remains debatable. Mannitol showed promising results in small retrospective series and might be a valid treatment modality (type C recommendation). However, the long treatment duration is a major drawback. Patients presenting without paresis can be treated with a platelet activating factor receptor antagonist (type C recommendation), since they seem to promote resolution of the haematoma, especially in patients with hygromas or low-density haematomas on computed tomography. Lastly, atorvastatin seems to be a safe option for the conservative treatment of asymptomatic or mildly symptomatic cSDH patients (type C recommendation). In conclusion, our knowledge of the conservative treatment modalities for cSDH is sparse and based on small case series and low grade evidence. However, some treatment modalities seem promising even in symptomatic patients with large haematomas. Randomised controlled trials are currently underway, and will hopefully provide us with good evidence for or against the conservative treatment of cSDH.

References

  1. Kudo H, Kuwamura K, Izawa I, Sawa H, Tamaki N. Chronic subdural hematoma in elderly people: present status on Awaji Island and epidemiological prospect. Neurol Med Chir (Tokyo). 1992;32(4):207–9. doi:.https://doi.org/10.2176/nmc.32.207 DOI: https://doi.org/10.2176/nmc.32.207
  2. Chen JC, Levy ML. Causes, epidemiology, and risk factors of chronic subdural hematoma. Neurosurg Clin N Am. 2000;11(3):399–406. DOI: https://doi.org/10.1016/S1042-3680(18)30101-3
  3. Santarius T, Kirkpatrick PJ, Kolias AG, Hutchinson PJ. Working toward rational and evidence-based treatment of chronic subdural hematoma. Clin Neurosurg. 2010;57:112–22.
  4. Soleman J, Taussky P, Fandino J, Muroi C. Evidence Based Treatment of Chronic Subdural Hematoma. In: Sadaka DF, editor. Traumatic Brain Injury: In Tech; 2014. DOI: https://doi.org/10.5772/57336
  5. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Rodríguez-Salazar A, Galacho-Harriero AM, Fernández-Arconada O. Dexamethasone treatment in chronic subdural haematoma. Neurocirugia (Astur). 2009;20(4):346–59. doi:.https://doi.org/10.1016/S1130-1473(09)70154-X DOI: https://doi.org/10.1016/S1130-1473(09)70154-X
  6. Frati A, Salvati M, Mainiero F, Ippoliti F, Rocchi G, Raco A, et al. Inflammation markers and risk factors for recurrence in 35 patients with a posttraumatic chronic subdural hematoma: a prospective study. J Neurosurg. 2004;100(1):24–32. doi:.https://doi.org/10.3171/jns.2004.100.1.0024 DOI: https://doi.org/10.3171/jns.2004.100.1.0024
  7. Glover D, Labadie EL. Physiopathogenesis of subdural hematomas. Part 2: Inhibition of growth of experimental hematomas with dexamethasone. J Neurosurg. 1976;45(4):393–7. doi:.https://doi.org/10.3171/jns.1976.45.4.0393 DOI: https://doi.org/10.3171/jns.1976.45.4.0393
  8. Nagatani K, Wada K, Takeuchi S, Nawashiro H. Corticosteroid suppression of vascular endothelial growth factor and recurrence of chronic subdural hematoma. Neurosurgery. 2012;70(5):E1334. [Author reply E-6.]. DOI: https://doi.org/10.1227/NEU.0b013e31824ae86a
  9. Labadie EL, Glover D. Local alterations of hemostatic-fibrinolytic mechanisms in reforming subdural hematomas. Neurology. 1975;25(7):669–75. doi:.https://doi.org/10.1212/WNL.25.7.669 DOI: https://doi.org/10.1212/WNL.25.7.669
  10. Katano H, Kamiya K, Mase M, Tanikawa M, Yamada K. Tissue plasminogen activator in chronic subdural hematomas as a predictor of recurrence. J Neurosurg. 2006;104(1):79–84. doi:.https://doi.org/10.3171/jns.2006.104.1.79 DOI: https://doi.org/10.3171/jns.2006.104.1.79
  11. Fujisawa H, Ito H, Saito K, Ikeda K, Nitta H, Yamashita J. Immunohistochemical localization of tissue-type plasminogen activator in the lining wall of chronic subdural hematoma. Surg Neurol. 1991;35(6):441–5. doi:.https://doi.org/10.1016/0090-3019(91)90177-B DOI: https://doi.org/10.1016/0090-3019(91)90177-B
  12. Hohenstein A, Erber R, Schilling L, Weigel R. Increased mRNA expression of VEGF within the hematoma and imbalance of angiopoietin-1 and -2 mRNA within the neomembranes of chronic subdural hematoma. J Neurotrauma. 2005;22(5):518–28. doi:.https://doi.org/10.1089/neu.2005.22.518 DOI: https://doi.org/10.1089/neu.2005.22.518
  13. Suzuki K, Takano S, Nose T, Doi M, Ohashi N. Increased concentration of vascular endothelial growth factor (VEGF) in chronic subdural hematoma [letter]. J Trauma. 1999;46(3):532–3. doi:.https://doi.org/10.1097/00005373-199903000-00040 DOI: https://doi.org/10.1097/00005373-199903000-00040
  14. Weigel R, Schilling L, Schmiedek P. Specific pattern of growth factor distribution in chronic subdural hematoma (CSH): evidence for an angiogenic disease. Acta Neurochir (Wien). 2001;143(8):811–8, discussion 819. doi:.https://doi.org/10.1007/s007010170035 DOI: https://doi.org/10.1007/s007010170035
  15. Stanisic M, Aasen AO, Pripp AH, Lindegaard KF, Ramm-Pettersen J, Lyngstadaas SP, et al. Local and systemic pro-inflammatory and anti-inflammatory cytokine patterns in patients with chronic subdural hematoma: a prospective study. Inflamm Res. 2012;61(8):845–52. doi:.https://doi.org/10.1007/s00011-012-0476-0 DOI: https://doi.org/10.1007/s00011-012-0476-0
  16. Xu XP, Liu C, Liu J, Pang YG, O XD, Fu J, et al. Local application of corticosteroids combined with surgery for the treatment of chronic subdural hematoma. Turk Neurosurg. 2015;25(2):252–5. doi:. https://doi.org/http://dx.doi.org.10.5137/1019-5149.JTN.8989-13.3
  17. Markwalder TM, Steinsiepe KF, Rohner M, Reichenbach W, Markwalder H. The course of chronic subdural hematomas after burr-hole craniostomy and closed-system drainage. J Neurosurg. 1981;55(3):390–6. doi:.https://doi.org/10.3171/jns.1981.55.3.0390 DOI: https://doi.org/10.3171/jns.1981.55.3.0390
  18. Kolias AG, Chari A, Santarius T, Hutchinson PJ. Chronic subdural haematoma: modern management and emerging therapies. Nat Rev Neurol. 2014;10(10):570–8. doi:.https://doi.org/10.1038/nrneurol.2014.163 DOI: https://doi.org/10.1038/nrneurol.2014.163
  19. Moher D, Liberati A, Tetzlaff J, Altman DG ; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336–41. doi:.https://doi.org/10.1016/j.ijsu.2010.02.007 DOI: https://doi.org/10.1016/j.ijsu.2010.02.007
  20. Guide to clinical preventive services. report of the U.S. Preventive Services Task Force. In: Force USPST, editor.: DIANE Publishing; 1989. p. 24, Appendix A.
  21. Lawrence R. Guide to Clinical Preventive Services. In: Edition USPSTF, editor.: DIANE Publishing; 1989.
  22. Soleman J, Lutz K, Schaedelin S, Mariani L, Fandino J. Use of Subperiosteal Drain Versus Subdural Drain in Chronic Subdural Hematomas Treated With Burr-Hole Trepanation: Study Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2016;5(2):e38. doi:.https://doi.org/10.2196/resprot.5339 DOI: https://doi.org/10.2196/resprot.5339
  23. Suzuki J, Takaku A. Nonsurgical treatment of chronic subdural hematoma. J Neurosurg. 1970;33(5):548–53. doi:.https://doi.org/10.3171/jns.1970.33.5.0548 DOI: https://doi.org/10.3171/jns.1970.33.5.0548
  24. Göksu E, Akyüz M, Uçar T, Kazan S. Spontaneous resolution of a large chronic subdural hematoma: a case report and review of the literature. Ulus Travma Acil Cerrahi Derg. 2009;15(1):95–8.
  25. Voelker JL. Nonoperative treatment of chronic subdural hematoma. Neurosurg Clin N Am. 2000;11(3):507–13. DOI: https://doi.org/10.1016/S1042-3680(18)30115-3
  26. Cenic A, Bhandari M, Reddy K. Management of chronic subdural hematoma: a national survey and literature review. Can J Neurol Sci. 2005;32(4):501–6. doi:.https://doi.org/10.1017/S0317167100004510 DOI: https://doi.org/10.1017/S0317167100004510
  27. Santarius T, Lawton R, Kirkpatrick PJ, Hutchinson PJ. The management of primary chronic subdural haematoma: a questionnaire survey of practice in the United Kingdom and the Republic of Ireland. Br J Neurosurg. 2008;22(4):529–34. doi:.https://doi.org/10.1080/02688690802195381 DOI: https://doi.org/10.1080/02688690802195381
  28. Juković M, Kojadinović Z, Popovska B, Till V. Complete spontaneous resolution of compressive chronic subdural hematoma in a patient with liver failure. Med Glas (Zenica). 2012;9(2):417–20.
  29. Parlato C, Guarracino A, Moraci A. Spontaneous resolution of chronic subdural hematoma. Surg Neurol. 2000;53(4):312–5, discussion 315–7. doi:.https://doi.org/10.1016/S0090-3019(00)00200-7 DOI: https://doi.org/10.1016/S0090-3019(00)00200-7
  30. Tiwari AR, Maheshwari S, Balasubramaniam S, Devendra T, Savant H. Spontaneous Resolution of Non Traumatic Chronic Subdural Haematoma Despite Continued Antiplatelet Therapy: A Case Report. J Clin Diagn Res. 2015;9(6):PD01–02. DOI: https://doi.org/10.7860/JCDR/2015/11864.6002
  31. Yang S, Zhang X, Jin Y. Spontaneous resolution of nontraumatic chronic subdural hematoma associated with anti-aggregation therapy. J Craniofac Surg. 2014;25(4):e363–5. doi:.https://doi.org/10.1097/SCS.0000000000000814 DOI: https://doi.org/10.1097/SCS.0000000000000814
  32. Lee KS. Natural history of chronic subdural haematoma. Brain Inj. 2004;18(4):351–8. doi:.https://doi.org/10.1080/02699050310001645801 DOI: https://doi.org/10.1080/02699050310001645801
  33. Naganuma H, Fukamachi A, Kawakami M, Misumi S, Nakajima H, Wakao T. Spontaneous resolution of chronic subdural hematomas. Neurosurgery. 1986;19(5):794–8. doi:.https://doi.org/10.1227/00006123-198611000-00013 DOI: https://doi.org/10.1227/00006123-198611000-00013
  34. Horikoshi T, Naganuma H, Fukasawa I, Uchida M, Nukui H. Computed tomography characteristics suggestive of spontaneous resolution of chronic subdural hematoma. Neurol Med Chir (Tokyo). 1998;38(9):527–32, discussion 532–3. doi:.https://doi.org/10.2176/nmc.38.527 DOI: https://doi.org/10.2176/nmc.38.527
  35. Emich S, Richling B, McCoy MR, Al-Schameri RA, Ling F, Sun L, et al. The efficacy of dexamethasone on reduction in the reoperation rate of chronic subdural hematoma--the DRESH study: straightforward study protocol for a randomized controlled trial. Trials. 2014;15(1):6. doi:.https://doi.org/10.1186/1745-6215-15-6 DOI: https://doi.org/10.1186/1745-6215-15-6
  36. Bender MB, Christoff N. Nonsurgical treatment of subdural hematomas. Arch Neurol. 1974;31(2):73–9. doi:.https://doi.org/10.1001/archneur.1974.00490380021001 DOI: https://doi.org/10.1001/archneur.1974.00490380021001
  37. Pichert G, Henn V. [Conservative therapy of chronic subdural hematomas]. Schweiz Med Wochenschr. 1987;117(47):1856–62.
  38. Sun TF, Boet R, Poon WS. Non-surgical primary treatment of chronic subdural haematoma: Preliminary results of using dexamethasone. Br J Neurosurg. 2005;19(4):327–33. doi:.https://doi.org/10.1080/02688690500305332 DOI: https://doi.org/10.1080/02688690500305332
  39. Almenawer SA, Farrokhyar F, Hong C, Alhazzani W, Manoranjan B, Yarascavitch B, et al. Chronic subdural hematoma management: a systematic review and meta-analysis of 34,829 patients. Ann Surg. 2014;259(3):449–57. doi:.https://doi.org/10.1097/SLA.0000000000000255 DOI: https://doi.org/10.1097/SLA.0000000000000255
  40. Thotakura AK, Marabathina NR. Nonsurgical Treatment of Chronic Subdural Hematoma with Steroids. World Neurosurg. 2015;84(6):1968–72. doi:.https://doi.org/10.1016/j.wneu.2015.08.044 DOI: https://doi.org/10.1016/j.wneu.2015.08.044
  41. Role of Dexamethasone in the Conservative Treatment of Chronic Subdural Hematoma. 2015 01.02.2016 [cited 26 Aug 2016]; Available from: https://clinicaltrials.gov/ct2/show/study/NCT02362321?term=chronic+subdural+hematoma&rank=15&sect=X370156
  42. Rudiger A, Ronsdorf A, Merlo A, Zimmerli W. Dexamethasone treatment of a patient with large bilateral chronic subdural haematomata. Swiss Med Wkly. 2001;131(25-26):387.
  43. Dran G, Berthier F, Fontaine D, Rasenrarijao D, Paquis P. Efficacité de la corticothérapie dans le traitement adjuvant des hématomes sous-duraux chroniques. Étude rétrospective sur 198 cas. [Effectiveness of adjuvant corticosteroid therapy for chronic subdural hematoma: a retrospective study of 198 cases]. Neurochirurgie. 2007;53(6):477–82. doi:.https://doi.org/10.1016/j.neuchi.2007.09.146 DOI: https://doi.org/10.1016/j.neuchi.2007.09.146
  44. Berghauser Pont LM, Dammers R, Schouten JW, Lingsma HF, Dirven CM. Clinical factors associated with outcome in chronic subdural hematoma: a retrospective cohort study of patients on preoperative corticosteroid therapy. Neurosurgery. 2012;70(4):873–80, discussion 880. doi:.https://doi.org/10.1227/NEU.0b013e31823672ad DOI: https://doi.org/10.1227/NEU.0b013e31823672ad
  45. Berghauser Pont LM, Dirven CM, Dippel DW, Verweij BH, Dammers R. The role of corticosteroids in the management of chronic subdural hematoma: a systematic review. Eur J Neurol. 2012;19(11):1397–403. doi:.https://doi.org/10.1111/j.1468-1331.2012.03768.x DOI: https://doi.org/10.1111/j.1468-1331.2012.03768.x
  46. Zarkou S, Aguilar MI, Patel NP, Wellik KE, Wingerchuk DM, Demaerschalk BM. The role of corticosteroids in the management of chronic subdural hematomas: a critically appraised topic. Neurologist. 2009;15(5):299–302. doi:.https://doi.org/10.1097/NRL.0b013e3181b65558 DOI: https://doi.org/10.1097/NRL.0b013e3181b65558
  47. Weigel R, Hohenstein A, Schlickum L, Weiss C, Schilling L. Angiotensin converting enzyme inhibition for arterial hypertension reduces the risk of recurrence in patients with chronic subdural hematoma possibly by an antiangiogenic mechanism. Neurosurgery. 2007;61(4):788–92, discussion 792–3. doi:.https://doi.org/10.1227/01.NEU.0000298907.56012.E8 DOI: https://doi.org/10.1227/01.NEU.0000298907.56012.E8
  48. Poulsen FR, Munthe S, Søe M, Halle B. Perindopril and residual chronic subdural hematoma volumes six weeks after burr hole surgery: a randomized trial. Clin Neurol Neurosurg. 2014;123:4–8. doi:.https://doi.org/10.1016/j.clineuro.2014.05.003 DOI: https://doi.org/10.1016/j.clineuro.2014.05.003
  49. Neidert MC, Schmidt T, Mitova T, Fierstra J, Bellut D, Regli L, et al. Preoperative angiotensin converting enzyme inhibitor usage in patients with chronic subdural hematoma: Associations with initial presentation and clinical outcome. J Clin Neurosci. 2016;28:82–6. doi:.https://doi.org/10.1016/j.jocn.2015.09.022 DOI: https://doi.org/10.1016/j.jocn.2015.09.022
  50. Kageyama H, Toyooka T, Tsuzuki N, Oka K. Nonsurgical treatment of chronic subdural hematoma with tranexamic acid. J Neurosurg. 2013;119(2):332–7. doi:.https://doi.org/10.3171/2013.3.JNS122162 DOI: https://doi.org/10.3171/2013.3.JNS122162
  51. Kinjo T, Sakurai Y, Ogawa A, Komatsu S, Suzuki J. [Nonsurgical treatment of chronic subdural hematoma. Sequential changes of computed tomography findings]. Neurol Med Chir (Tokyo). 1985;25(8):645–53. doi:.https://doi.org/10.2176/nmc.25.645 DOI: https://doi.org/10.2176/nmc.25.645
  52. Hirashima Y, Kurimoto M, Nagai S, Hori E, Origasa H, Endo S. Effect of platelet-activating factor receptor antagonist, etizolam, on resolution of chronic subdural hematoma--a prospective study to investigate use as conservative therapy. Neurol Med Chir (Tokyo). 2005;45(12):621–6, discussion 626. doi:.https://doi.org/10.2176/nmc.45.621 DOI: https://doi.org/10.2176/nmc.45.621
  53. Hirashima Y, Kuwayama N, Hamada H, Hayashi N, Endo S. Etizolam, an anti-anxiety agent, attenuates recurrence of chronic subdural hematoma--evaluation by computed tomography. Neurol Med Chir (Tokyo). 2002;42(2):53–5, discussion 56. doi:.https://doi.org/10.2176/nmc.42.53 DOI: https://doi.org/10.2176/nmc.42.53
  54. Li T, Wang D, Tian Y, Yu H, Wang Y, Quan W, et al. Effects of atorvastatin on the inflammation regulation and elimination of subdural hematoma in rats. J Neurol Sci. 2014;341(1-2):88–96. doi:.https://doi.org/10.1016/j.jns.2014.04.009 DOI: https://doi.org/10.1016/j.jns.2014.04.009
  55. Wang D, Li T, Tian Y, Wang S, Jin C, Wei H, et al. Effects of atorvastatin on chronic subdural hematoma: a preliminary report from three medical centers. J Neurol Sci. 2014;336(1-2):237–42. doi:.https://doi.org/10.1016/j.jns.2013.11.005 DOI: https://doi.org/10.1016/j.jns.2013.11.005
  56. Min X, Pin C, Xun Z, Cun-Zu W, Xue-Qiang S, Bo Y. Effects of atorvastatin on conservative and surgical treatments of chronic subdural hematoma in patients. World Neurosurg. 2016;91:23–8. doi:http://dx.doi.org/10.1016/j.wneu.2016.03.067. DOI: https://doi.org/10.1016/j.wneu.2016.03.067
  57. Iorio-Morin C, Blanchard J, Richer M, Mathieu D. Tranexamic Acid in Chronic Subdural Hematomas (TRACS): study protocol for a randomized controlled trial. Trials. 2016;17(1):235. doi:.https://doi.org/10.1186/s13063-016-1358-5 DOI: https://doi.org/10.1186/s13063-016-1358-5
  58. Jiang R, Wang D, Poon WS, Lu YC, Li XG, Zhao SG, et al. Effect of ATorvastatin On Chronic subdural Hematoma (ATOCH): a study protocol for a randomized controlled trial. Trials. 2015;16(1):528. doi:.https://doi.org/10.1186/s13063-015-1045-y DOI: https://doi.org/10.1186/s13063-015-1045-y

Most read articles by the same author(s)